Dogwood Therapeutics, Inc. (NASDAQ:DWTX – Free Report) – Stock analysts at Zacks Small Cap reduced their FY2024 EPS estimates for Dogwood Therapeutics in a research report issued on Monday, November 11th. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings of ($6.43) per share for the year, down from their prior estimate of ($5.71). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($5.84) per share.
Dogwood Therapeutics Stock Performance
Dogwood Therapeutics stock opened at $2.97 on Wednesday. The firm has a market capitalization of $3.95 million, a price-to-earnings ratio of -0.50 and a beta of 1.57. Dogwood Therapeutics has a 1-year low of $2.50 and a 1-year high of $23.50.
Dogwood Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Stories
- Five stocks we like better than Dogwood Therapeutics
- Following Congress Stock Trades
- Rocket Lab is the Right Stock for the Right Time
- Low PE Growth Stocks: Unlocking Investment Opportunities
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Find and Profitably Trade Stocks at 52-Week Lows
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
